Prostate cancer recurrent
|
0.100 |
Biomarker
|
disease |
BEFREE |
The PSMA positivity rate for PC was significantly higher in dPET/CT for the lowest PSA values (PSA < 2.0 ng/ml, p < 0.05).
|
31792572 |
2020 |
Prostate cancer recurrent
|
0.100 |
Biomarker
|
disease |
BEFREE |
Radio-recurrent prostate cancer is typically detected by a rising PSA and may reflect local or distant disease.
|
31730876 |
2020 |
Prostate cancer recurrent
|
0.100 |
Biomarker
|
disease |
BEFREE |
<sup>68</sup>Ga-PSMA-11 PET/CT in recurrent prostate cancer: efficacy in different clinical stages of PSA failure after radical therapy.
|
30350010 |
2019 |
Prostate cancer recurrent
|
0.100 |
Biomarker
|
disease |
BEFREE |
Local recurrent prostate cancer after radical treatment is found in the majority of men with a rising PSA.
|
30788590 |
2019 |
Prostate cancer recurrent
|
0.100 |
Biomarker
|
disease |
BEFREE |
Single Lesion on Prostate-specific Membrane Antigen-ligand Positron Emission Tomography and Low Prostate-specific Antigen Are Prognostic Factors for a Favorable Biochemical Response to Prostate-specific Membrane Antigen-targeted Radioguided Surgery in Recurrent Prostate Cancer.
|
30987843 |
2019 |
Prostate cancer recurrent
|
0.100 |
Biomarker
|
disease |
BEFREE |
Effect of early salvage radiotherapy at PSA < 0.5 ng/ml and impact of post-SRT PSA nadir in post-prostatectomy recurrent prostate cancer.
|
30487644 |
2019 |
Prostate cancer recurrent
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The aim of our study was to evaluate correlations between PSA levels and standardized uptake values (SUV) in patients with recurrent prostate cancer.
|
31568268 |
2019 |
Prostate cancer recurrent
|
0.100 |
Biomarker
|
disease |
BEFREE |
The primary outcome measure was to determine the relationship between pre-scan PSA and the probability of identifying PSMA-avid disease suggestive of recurrent prostate cancer.
|
31363165 |
2019 |
Prostate cancer recurrent
|
0.100 |
Biomarker
|
disease |
BEFREE |
68Ga-PSMA PET/CT Urachus Metastases in Recurrent Prostate Cancer With Very Low PSA Level.
|
30540597 |
2019 |
Prostate cancer recurrent
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
<b>Conclusion:</b> We have shown, in a large cohort of patients, that 68Ga-PSMA-11 PET/CT is a sensitive tool for restaging PC and has a high detection efficacy, even in patients with very low PSA levels (<0.2 ng/ml).
|
31693724 |
2019 |
Prostate cancer recurrent
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Detection of recurrent prostate cancer using F-fluciclovine PET/CT is possible in patients with low but rising PSA levels of 1 ng/mL or less.
|
30589673 |
2019 |
Prostate cancer recurrent
|
0.100 |
Biomarker
|
disease |
BEFREE |
Trigger PSA is an important risk factor for positive findings of Choline PET/CT and the detection rate of Choline PET/CT for recurrent prostate cancer increased in parallel with raises in PSA-values.
|
29581869 |
2018 |
Prostate cancer recurrent
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thirty patients (median prostate-specific antigen [PSA: 11.8 ng/mL]) with suspected recurrent prostate cancer following definitive treatment underwent <sup>11</sup>C-choline PET/CT and conventional imaging, including pelvic MRI, contrast-enhanced chest, abdomen, and pelvic CT, and bone scintigraphy.
|
30210954 |
2018 |
Prostate cancer recurrent
|
0.100 |
Biomarker
|
disease |
BEFREE |
Prostatic acid phosphatase (PAP) is a prostate tumor antigen, and the target of the only FDA-approved anti-tumor vaccine, sipuleucel-T. We have previously reported in two clinical trials that a DNA vaccine encoding PAP (pTVG-HP) could elicit PAP-specific, Th1-biased T cells in patients with PSA-recurrent prostate cancer.
|
29534736 |
2018 |
Prostate cancer recurrent
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Recently, prostate-specific membrane antigen (PSMA)-based imaging modalities such as PSMA PET/CT and PET/MRI have received significant attention for detection of recurrent prostate cancer sites with elevated prostate-specific antigen levels, after therapy.
|
30124601 |
2018 |
Prostate cancer recurrent
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Fluciclovine, also known as anti-1-amino-3-[<sup>18</sup>F]-fluorocyclobutane-1-carboxylic acid (Axumin), is a new PET radiotracer approved by the Food and Drug Administration in 2016 for the detection of suspected recurrent prostate cancer with elevated prostate-specific antigen levels.
|
30077749 |
2018 |
Prostate cancer recurrent
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our data show that <sup>68</sup>Ga-PSMA-11 PET/MRI has a high detection rate for recurrent prostate cancer even at very low PSA levels <0.5 ng/mL.
|
29032394 |
2018 |
Prostate cancer recurrent
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition, to determine the success of <sup>111</sup> In-PSMA-RGS with regard to postoperative prostate-specific antigen (PSA) responses, PCa-specific treatment-free survival rates and postoperative complication rates.
|
27862863 |
2017 |
Prostate cancer recurrent
|
0.100 |
Biomarker
|
disease |
BEFREE |
Further optimization of the tumor-to-background contrast might significantly enhance the sensitivity of PET/CT imaging and the probability of detecting recurrent prostate cancer at low PSA values.
|
28787147 |
2017 |
Prostate cancer recurrent
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Ga-PSMA PET/CT was performed in a 68-year-old man to evaluate recurrent prostate cancer due to elevated serum prostate-specific antigen level.
|
28319497 |
2017 |
Prostate cancer recurrent
|
0.100 |
Biomarker
|
disease |
BEFREE |
Retrospective review of 184 patients with a rising prostate-specific antigen (PSA) after RT for CaP.
|
27597240 |
2017 |
Prostate cancer recurrent
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We treated 20 patients who had recurrent prostate cancer with 200 μmoles/day of sulforaphane-rich extracts for a maximum period of 20 weeks and determined the proportion of patients with ≥50% PSA declines, the primary endpoint.
|
25431127 |
2015 |
Prostate cancer recurrent
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Metastasis-free survival is associated with overall survival in men with PSA-recurrent prostate cancer treated with deferred androgen deprivation therapy.
|
23946329 |
2013 |
Prostate cancer recurrent
|
0.100 |
Biomarker
|
disease |
BEFREE |
We evaluated the efficacy of isoflavone in patients with PSA recurrent prostate cancer after prior therapy.
|
18471323 |
2008 |
Prostate cancer recurrent
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
PCA3 and PSA mRNAs were undetectable in postprostatectomy specimens except for one man with recurrent prostate cancer.Assay interrun CVs were < or =12%.
|
16627561 |
2006 |